HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.
2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Medical Oncology: Chemotherapy, targeted therapies, and combination regimens.
Medical Oncology: Chemotherapy, targeted therapies, and combination regimens.
Medical oncology continues to evolve with advancements in chemotherapy, targeted therapies, and combination regimens. Case studies often focus on individualized treatment plans based on genetic and molecular tumor profiling, such as using EGFR inhibitors for non-small cell lung cancer. Combination regimens, like adding bevacizumab to chemotherapy, demonstrate enhanced efficacy for certain cancers. Additionally, the use of maintenance therapies prolongs progression-free survival in metastatic cases. These developments underscore the critical role of medical oncology in providing systemic treatments that complement surgical and radiation approaches, ensuring comprehensive cancer care tailored to each patient’s needs.
Committee Members
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States CIOC 2026 Speakers
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China